Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 8Gastrointestinal 6Breast 6Genitourinary 3NET 2Endocrine 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1CNS 1

Conditions

Neuroendocrine Tumors 2

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Liquid Biopsy × Endocrine × Clear all
NCT05255133 2025-01-06

Liquid-NET

Universiteit Antwerpen

Phase NA Completed
22 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05268952 2022-03-07

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

University Hospital, Antwerp

Phase NA Unknown
100 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡